CO7131381A2 - Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto - Google Patents

Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto

Info

Publication number
CO7131381A2
CO7131381A2 CO14252512A CO14252512A CO7131381A2 CO 7131381 A2 CO7131381 A2 CO 7131381A2 CO 14252512 A CO14252512 A CO 14252512A CO 14252512 A CO14252512 A CO 14252512A CO 7131381 A2 CO7131381 A2 CO 7131381A2
Authority
CO
Colombia
Prior art keywords
growth factor
fibroblast growth
therapeutic uses
factor proteins
proteins
Prior art date
Application number
CO14252512A
Other languages
English (en)
Spanish (es)
Inventor
Yanfel Linda Ma
Rovira Armando Rafael Irizarre
Vincent Louis Reynolss
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7131381(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO7131381A2 publication Critical patent/CO7131381A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CO14252512A 2012-05-15 2014-11-14 Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto CO7131381A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US201361786939P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CO7131381A2 true CO7131381A2 (es) 2014-12-01

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14252512A CO7131381A2 (es) 2012-05-15 2014-11-14 Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto

Country Status (21)

Country Link
US (1) US20150141335A1 (enExample)
EP (1) EP2852398A1 (enExample)
JP (1) JP2015522539A (enExample)
KR (1) KR20150002801A (enExample)
CN (1) CN104302311A (enExample)
AU (1) AU2013263188A1 (enExample)
BR (1) BR112014028413A2 (enExample)
CA (1) CA2869320A1 (enExample)
CL (1) CL2014002846A1 (enExample)
CO (1) CO7131381A2 (enExample)
EA (1) EA201491856A1 (enExample)
HK (1) HK1202800A1 (enExample)
IL (1) IL235482A0 (enExample)
MA (1) MA37506B1 (enExample)
MX (1) MX2014013913A (enExample)
PE (1) PE20142432A1 (enExample)
PH (1) PH12014502537A1 (enExample)
SG (1) SG11201407655TA (enExample)
TN (1) TN2014000409A1 (enExample)
WO (1) WO2013173158A1 (enExample)
ZA (1) ZA201407532B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10293026B2 (en) 2014-09-08 2019-05-21 Osaka University Agent for preventing or treating demyelinating disease
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523084A (ja) * 2007-03-30 2010-07-15 アンブルックス,インコーポレイテッド 修飾fgf−21ポリペプチド
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
JP2015522539A (ja) 2015-08-06
ZA201407532B (en) 2016-05-25
IL235482A0 (en) 2014-12-31
PE20142432A1 (es) 2015-01-22
CA2869320A1 (en) 2013-11-21
KR20150002801A (ko) 2015-01-07
HK1202800A1 (en) 2015-10-09
WO2013173158A1 (en) 2013-11-21
CN104302311A (zh) 2015-01-21
SG11201407655TA (en) 2014-12-30
MX2014013913A (es) 2015-02-17
PH12014502537A1 (en) 2015-01-21
TN2014000409A1 (en) 2015-12-21
CL2014002846A1 (es) 2015-01-30
EA201491856A1 (ru) 2015-03-31
MA37506B1 (fr) 2017-03-31
US20150141335A1 (en) 2015-05-21
MA37506A1 (fr) 2016-01-29
BR112014028413A2 (pt) 2017-11-07
EP2852398A1 (en) 2015-04-01
AU2013263188A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
CO7131381A2 (es) Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
IN2014DN08812A (enExample)
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EP2768514A4 (en) LOCALIZED MODULATION OF TISSUES AND CELLS TO IMPROVE THERAPEUTIC EFFECTS INCLUDING RENAL RECURRING
MX379235B (es) Compuestos y sus usos para modular la hemoglobina.
UY34663A (es) Acido nucleico y proteina recombinante del gen de la endotoxina axmi345, vectores, células, composiciones y métodos para proteger plantas
MX388013B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
EA201590115A8 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
PH12014501702A1 (en) Imidazopyrrolidinone compounds
HK1206638A1 (zh) 用於生产化妆品蛋白质和肽的修饰的多核苷酸
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2022013454A (es) Moduladores de la actividad del complemento.
EA202092627A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
MX359769B (es) Metodos para descelularizar huesos.
CO7091179A2 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MX2015007719A (es) Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
HUE043419T2 (hu) Vegyületek remielinizációs blokk kezelésére HERV-W borítékfehérje expresszióval járó betegségekben